After years of delays Pfizer and Eli Lilly’s tanezumab non-opioid pain ... Regeneron is developing its rival anti-NGF antibody fasinumab but earlier this year halted higher dose arms of its ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, one of two remaining drugs in the ill-fated nerve growth factor (NGF) inhibitor class.

Jim Cramer says the Fed action is great news for high-growth tech stocks, which should be among the first sectors to recover.